Sulforaphane inhibited expression of hypoxia-inducible factor-1α in human tongue squamous cancer cells and prostate cancer cells

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1255-1261

  Yao, Hua ^a,b   Wang, Huiming ^b   Zhang, Zhuo ^a   Jiang, Bing Hua ^c   Luo, Jia ^c   Shi, Xianglin ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

(HIF 1 ); Cancer; Chemopreventive; Hypoxia inducible factor 1 ; Sulforaphane

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SULFORAPHANE; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA;

ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MAP KINASE KINASE 4; NEOPLASMS, SQUAMOUS CELL; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIOCYANATES; TONGUE NEOPLASMS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49749150144     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23647     Document Type: Article

References (54)

1. Chin D, Boyle GM. Head and neck cancer: past, present and future. Expert Rev Anticancer 2006;6:1111-8.
2. Kademani D. Oral cancer. Mayo Clin Proc 2007;82:878-87.
3. Kademani D, Baltali E, Lewis J, Keller E. Analysis of death certification in patients with early stage oral cavity squamous cell carcinoma. J Oral Maxillofac Surg 2007;65:1191-7.
4. Lo Muzio L, Santarelli A, Panzarella V, Campisi G, Carella M, Ciavarella D, Di Cosola M, Giannone N, Bascones A. Oral squamous cell carcinoma and biological markers: an update on the molecules mainly involved in oral carcinogenesis. Minerva Stomatol 2007;56:341-7.
5. American Cancer Society Cancer. Cancer facts and figures. Atlanta, GA: American Cancer Society, 2007.
6. Cancer trends progress report-2005 update. National Cancer Institute, NIH, DHHS, Bethesda, MD. 2005.
7. Xu H, Zhang X, Farahvash B. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 2007;178:1846-54.
8. Liu A, Pajkovic N, Pang Y, Zhu D, Calamini B, Mesecar AL, van Breemen RB. Absorption and subcellular localization of lycopene in human prostate cancer cells. Mol Cancer Ther 2006;5:2879-85.
9. Pathak SK, Sharma RA, Mellon J. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation [review]. Int J Oncol 2003;22:5-13.
10. Klein EA. Can prostate cancer be prevented? Nat Clin Pract Urol 2005;2:24-31.
11. Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res 2007;67:7815-24.
12. Fimognar C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res/Rev Mutat Res 2007;635:90-104.
13. Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 2005;280:19911-24.
14. Shen G, Khor TO, Hu R. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 2007;67:9937-44.
15. Mi L, Wang X, Govind S. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells. Cancer Res 2007;67:6409-16.
16. Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. Mol Cancer Ther 2007;6: 1673-81.
17. Choi S, Singh SV. Bax and bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable derived cancer chemopreventive agent. Cancer Res 2005;65:2035-43.
18. Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, Singh SV. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 2007;28:151-62.
19. Herman-Antosiewicz A, Johnson DE, Singh S. Sulforaphane causes autophagy to inhibit release of cytochrome c and apoptosis in human prostate cancer cells. Cancer Res 2006;66:5828-35.
20. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1. LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006;27:811-9.
21. Semenza GL. Life with oxygen. Science 2007;318:62-4.
22. Monsef N, Helczynski L, Lundwall A, PÅhlman S. Anders-bjartell: localization of immunoreactive HIF-1α and HIF-2α in neuroendocrine cells of both benign and malignant prostate glands. Prostate 2007;67:1219-29.
23. Hatake K, Tokudome N, Ito Y. Next generation molecular targeted agents for breast cancer, focus on EGER and VEGFR pathways. Breast Cancer 2007;14:132-49.
24. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P. Hypoxia inducible factor-1 alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 2006;99:135-41.
25. Brennan PA, Mackenzie N, Quintero M. Hypoxia-inducible factor lalpha in oral cancer. J Oral Pathol Med 2005;34:385-9.
26. Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le Floch R, Yang J, Ashcroft M. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 2007;26:3920-9.
27. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006;66:6264-70.
28. Li ZD, Liu LZ, Shi X, Fang J, Jiang BH. Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation. Biochem Biophys Res Commun 2007;357:517-23.
29. Fu B, Xue J, Li Z, Shi X, Jiang BH, Fang J. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 2007;6:220-6.
30. Slomiany MG, Black LA, Kibbey MM, Day TA, Rosenzweig SA. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 2006;342:851-8.
31. Zhou Q, Liu LZ, Fu B, Hu X, Shi X, Fang J, Jiang BH. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007;28:28-37.
32. Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofac Surg 2007;65:17-21.
33. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
34. Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer 2007;110:1889-99.
35. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Fruits and vegetables and endometrial cancer risk: a systematic literature review and meta-analysis. Nutr Cancer 2007;58:6-21.
36. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007;67: 4303-10.
37. Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, Bojanowski MW, Gingras D, Béliveau R. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 2005;26:821-6.
38. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005;16:901-9.
39. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005;19:342-53.
40. Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215-21.
41. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
42. Chaudhuri D, Orsulic S, Ashok BT. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol Cancer Ther 2007;6:334-45.
43. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 2007;28:1485-90.
44. Fimognari C, Nüsse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 2002; 23:581-6.
45. Brigelius-Flohé R, Banning A. Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free Radic Res 2006;40:775-87.
46. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 2007;6:1013-21.
47. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20: 5197-206.
48. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim AV, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
49. Thomas R, Kim MH. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 2005;334:543-8.
50. Xu C, Shen G, Yuan X, Kim JH, Gopalkrishnan A, Keum YS, Nair S, Kong AN. ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 2006;27: 437-45.
51. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274:32631-37.
52. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000;275:26484-91.
53. Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y. Vitexin, a HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Mol Cells 2006;22:291-9.
54. Liu C, Shi Y, Du Y, Ning X, Liu N, Huang D, Liang J, Xue Y, Fan D. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp Cell Res 2005;309:410-8.